secwatch / observer
8-K filed Feb 25, 2025 23:59 UTC ticker CBIO CIK 0001253689
other_material confidence high sentiment negative materiality 0.85

GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart

CRESCENT BIOPHARMA, INC.

item 1.02item 5.02

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001558370-25-001517
form_type
8-K
ticker
CBIO
cik
0001253689
company_name
CRESCENT BIOPHARMA, INC.
filed_at
2025-02-25T23:59:59+00:00
discovered_at
2026-05-14T18:03:03.146114+00:00
generated_at
2026-05-26T04:26:32.456713+00:00
sec_items
["1.02", "5.02"]
event_type
other_material
sentiment
negative
materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001558370-25-001517
json_url
https://secwatch.observer/filing/0001558370-25-001517.json
markdown_url
https://secwatch.observer/filing/0001558370-25-001517.md
text_url
https://secwatch.observer/filing/0001558370-25-001517.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/glyc-20250219x8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rachel King

Director
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Departed

Harout Semerjian

Director
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.
Departed

Mark Goldberg

Director
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Departed

Scott Jackson

Director
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Departed

Brian Hahn

Chief Financial Officer
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
Departed

Harout Semerjian

Chief Executive Officer
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
Departed

Scott Koenig

Director
CBIO · CRESCENT BIOPHARMA, INC.
Effective
2025-02-21
Filed
Feb 25, 2025 23:59 UTC
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.

Source-grounded claims

226bee0065

Rachel King resigned as Director at CRESCENT BIOPHARMA, INC..

each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

290de6af05

Harout Semerjian resigned as Director at CRESCENT BIOPHARMA, INC..

Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

3e0859b4b4

Mark Goldberg resigned as Director at CRESCENT BIOPHARMA, INC..

each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

55d17dab71

Scott Jackson resigned as Director at CRESCENT BIOPHARMA, INC..

each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

816677156a

Brian Hahn departed as Chief Financial Officer at CRESCENT BIOPHARMA, INC..

each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

860c9512d0

Harout Semerjian departed as Chief Executive Officer at CRESCENT BIOPHARMA, INC..

each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

fdfccd119c

Scott Koenig resigned as Director at CRESCENT BIOPHARMA, INC..

each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR
accession 0001558370-25-001517
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.